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ABSTRACT 
Background 
Chromosomal abnormalities in childhood acute lymphoblastic leukaemia are well 
established disease markers and indicators of outcomes. However, the long term 
prognosis and independent prognostic effect of some abnormalities has been questioned. 
Also less is known about the relationship between cytogenetics and the characteristics of 
relapse (time and site of relapse) known to predict outcome post-relapse.  
Patients and Methods 
We analysed cytogenetic data from 1725 children with B-cell precursor acute 
lymphoblastic leukaemia treated on MRC ALL97; with a median follow-up time of 8.2 
years. Univariate and multivariate analysis were used to examine the risk of relapse, 
event free and overall survival of 21 individual chromosomal abnormalities and three 
cytogenetic risk groups. 
Findings 
Analysis showed that two chromosomal abnormalities were associated with a 
significantly superior outcome whereas five were associated with an increased risk of 
relapse: ETV6-RUNX1 – HR=0.51 (95% CI 0.38,0.70), High hyperdiploidy – 0.60 
(0.47,0.78), iAMP21 – 6.04 (3.90,9.35), t(9;22) – 3.55 (2.21,5.72), MLL translocations 
– 2.98 (1.71,5.20), abnormal 17p – 2.09 (1.30,3.37) and loss of 13q – 1.87 (1.09,3.20). 
Multivariate analysis incorporating age, white cell count and treatment parameters 
revealed that six cytogenetic parameters (ETV6-RUNX1, high hyperdiploidy, iAMP21, 
t(9;22), loss of 13q and abnormal 17p) retained their significance for increased relapse 
risk. Based on these data, patients were classified into good, intermediate and poor 
cytogenetic risk groups. Slow early treatment response correlated with cytogenetic risk 
group: 34/460 (7%), 22/211 (10%) and 27/95 (28%) respectively (p<0.0001). In 
addition, the proportion suffering a very early (<18m) relapse varied by cytogenetic risk 
group: 8/129 (6%), 24/98 (25%) and 37/82 (45%) respectively (p<0.0001). However, 
there was no difference in the site of relapse by cytogenetic risk group.  
Interpretation 
Individual chromosomal abnormalities are strong independent indicators of outcome, 
especially risk of relapse. Diagnostic cytogenetics not only identifies patients with a 
higher rate of relapse but also those who are likely to suffer a “high risk” relapse.  
This research was funded by Leukaemia and Lymphoma Research (LLR).  
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INTRODUCTION 
Acute lymphoblastic leukaemia (ALL) is a heterogeneous disease at the cytogenetic and 
genetic levels.1 Numerous acquired genetic abnormalities have been described in the 
bone marrow cells of patients with ALL; including chromosomal translocations, 
aneuploidy, deletions and amplifications. Several genetic aberrations are pathognomic of 
the disease and can be used to monitor the patient’s response to therapy. Along with 
treatment regimen, age, white count cell (WCC) and minimal residual disease (MRD) 
detection, the genetic profile of the leukaemia is a major determinant of clinical outcome, 
especially the risk of relapse.2 Improvements in the design and delivery of frontline 
protocols for paediatric ALL have increased survival rates steadily over the past four 
decades.2 Despite these advances, 15%-20% of children with ALL will suffer a relapse.3 
The continued refinement and monitoring of prognostic factors is warranted to update 
risk stratification algorithms in the light of new discoveries and evaluate their role in the 
context of revised and developing protocols.  
Recent studies have suggested that the strongest risk factors for survival after a first 
relapse are the length of the first remission and the site of relapse.3 Several clinical 
study groups have proposed relapse risk classifications based on these factors along with 
immunophenotype.3 Increasingly, these relapse risk groups are being used to direct post 
relapse therapy, especially the use of stem cell transplantation. However, there are no 
studies examining the association between cytogenetics and these relapse risk groups.  
In this study, we present outcome data from the MRC ALL97/99 paediatric trial stratified 
by specific chromosomal abnormalities and cytogenetic risk group. In addition, we 
examine the relationship between presentation cytogenetics and relapse risk group. 
 
PATIENTS AND METHODS 
Study Population and treatment 
Between April 1997 and June 2002, 1725 children with B-cell precursor ALL (BCP-ALL) 
and aged 1-18 years old were treated on the MRC ALL97 and ALL99 phases of the trial 
(Figure 1). Infants under the age of one year were not eligible for this trial. Centres 
obtained local ethical committee approval and written informed consent from patients or 
parents. Full treatment protocols and overall results have been published.4-6 Both phases, 
ALL97 and ALL99, included a steroid and purine randomisation: prednisolone / 
dexamethasone and mercaptopurine / thioguanine in induction and maintenance. In 
ALL97, patients received a four drug induction followed by two or three intensification 
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blocks, appropriate CNS directed treatment and continuing therapy for a total of 2 years. 
High risk patients were identified by the Oxford Hazard Score (based on age, gender and 
white cell count (WCC)) or by the presence of t(9;22)(q34;q11.2)/BCR-ABL1, near 
haploidy (<30 chromosomes), low hypodiploidy (30-39 chromosomes) or MLL/11q23 
translocations (under 2 years old) and were transferred to a more intensive protocol 
(HR1).5 In ALL99, children were stratified on the basis of age and WCC to regimen A 
(<10 years and <50x109/L) or regimen B (all others). Patients received a three/four 
(regimen A/B) drug induction and were classified as a slow early responder (SER) if the 
day 15/8 (regimen A/B) marrow contained 25% blasts of higher. Patients who failed to 
remit, were SERs or had t(9;22), near haploidy, low hypodiploidy or MLL/11q23 
translocations (under 2 years old) were transferred to the more intensive regimen C. 
After induction, patients received consolidation, two interim maintenance blocks, two 
delayed intensification blocks and continuing therapy for up to 2 years (girls) or 3 years 
(boys). All patients treated on HR-1 were eligible for CR1 sibling allogeneic 
transplantation but only failure to achieve remission at day 29 and presence of 
t(9;22)(q34;q11.2)/BCR-ABL1 were indications in ALL99. 
Cytogenetics 
Cytogenetic analyses were performed on the pre-treatment bone marrow or blood 
samples of 1694/1725 (98%) patients by member laboratories of the UK Cancer 
Cytogenetics Group (UKCCG) (n=30) whose satisfactory performance was monitored by 
a national external quality assurance scheme: UK National External Quality Assessment 
Service (NEQAS) for Clinical Cytogenetics.7 The results were collected centrally by the 
Leukaemia Research Cytogenetics Research Group (LRCG).8 Karyotypes were not 
routinely analyzed centrally, but were reviewed for accuracy in description of the 
structural and numerical, clonal chromosomal abnormalities, which were reported in 
accordance with the International System for Human Cytogenetic Nomenclature (ISCN).9 
Analysis of fewer than 20 normal metaphases was classified as a failure, which occurred 
in 275/1694 (16%) cases. A normal karyotype (20 or more normal metaphases) was 
present in 219/1419 (15%) cases. A clonal abnormality was detected in 1200/1419 
(85%) cases. Fluorescence in situ hybridisation (FISH) testing was performed locally or 
centrally by the LRCG as previously described.10 FISH for ETV6-RUNX1, BCR-ABL1 and 
MLL was performed on 1451 (84%), 1448 (84%) and 1431 (83%) respectively, using 
commercial fusion or break-apart probes as previously described.10 The Multiprobe-I 
system for the detection of aneuploidy was performed on 265 (15%) cases with failed or 
incomplete cytogenetics or a normal karyotype. Each patient was classified according to 
whether each chromosomal abnormality was present, absent or had not been 
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appropriately tested. Chromosomal abnormalities were classified as primary or 
secondary based on prior knowledge.1 Analysis of secondary abnormalities was restricted 
to those that were present in 10 or more cases.  
Statistics and Endpoints 
Event free survival (EFS) and overall survival (OS) were defined as the time from the 
start of treatment to relapse/death and death, respectively. Relapse free survival (RFS) 
was calculated only for patients who achieved a complete remission and was defined as 
the time from the date of complete remission until relapse; with deaths in first remission 
being censored. Patients without an event of interest were censored at the date of last 
contact or date of second neoplasm whichever was earlier. A second neoplasm was 
diagnosed in 11 (<1%) patients. RFS, EFS and OS survival estimates were calculated 
using the Kaplan-Meier method. Hazard ratios comparing RFS, EFS and OS between 
subgroups were calculated using univariate Cox models.  Multivariate Cox regression 
modelling was performed for RFS, EFS and OS using a forward-selection stepwise 
modelling process; the difference in the log likelihood (-2*LogLikelihood) was used along 
with an adjustment for steroid randomisation (dexamethasone versus prednisolone) and 
phase of trial (ALL99 versus ALL97). Age and a log transformed WCC factor were 
modelled as continuous variables, while all other factors were categorical variables. All 
variables in the model were linear and conformed to the proportional hazards 
assumption. Interaction between treatment protocol and cytogenetic parameters were 
explored by the addition of an interaction term in the final model and inspecting its effect 
on the log likelihood. Only the following cytogenetic variables were considered in the 
model – high hyperdiploidy (51-65 chromosomes), ETV6-RUNX1, MLL translocations, 
iAMP21, t(9;22), abnormal 17p and loss of 13q. Not all cases were screened for all 
possible abnormalities (see cytogenetics paragraph above). As complete data is required 
to include a case in the model, we adopted two strategies - imputing missing values and 
reducing the dataset to cases with complete information. We performed both methods as 
each has implications in terms of bias. The results obtained were very similar. We opted 
to present the results from the “imputed” analysis because they were based on a larger 
number of cases and hence generated more precise estimates. Among the 1546 cases 
used for the modelling, 1233 (80%) had complete information. Imputing was based on 
the assumption of mutual exclusivity, which is supported by the data in Supplementary 
Table 1. Thus cases with one primary chromosomal abnormality were classified as 
negative for the presence of other primary chromosomal abnormalities. The number of 
cases imputed as absent were: high hyperdiploidy (n=79); ETV6-RUNX1 (n=188); 
t(9;22) (n=5); iAMP21 (n=219); MLL translocations (n=9). In addition, 127 cases with 
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failed cytogenetics were classified as negative for abnormal 17p and loss of 13q. While a 
more stringent multiple comparisons adjustment might be applicable in a classical 
setting, because of the investigative nature of this analysis, all tests were conducted at 
the 1% significance level. All analyses were performed using Intercooled Stata 11.0 for 
Windows (Stata Corporation, College Station, Texas, USA).Role of the funding source 
The funding source had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the decision to submit the paper for 
publication. 
 
RESULTS 
Survival estimates for the whole cohort of 1725 patients at 5 years were: RFS 81% (79-
83%); EFS 78% (95% CI 76-80%); and OS 87% (86-89%) after a median follow-up 
time of 8.2, 8.3 and 8.4 years respectively. In total there were 351 (20%) relapses, 16 
(1%) non-remitters and 257 (15%) deaths including 57 (3%) in first remission. Patients 
treated on the ALL99 phase of the trial had a significantly improved outcome compared 
to those treated on the ALL97 phase: RFS 84% (81-87%) v 78% (75-81%) (p=0.003); 
EFS 81% (78-83%) v 75% (72-78%) (p=0.005); OS 90% (87-91%) v 85% (83-88%) 
(p=0.014). 
On the basis of cytogenetic and FISH data 1269/1694 (75%) cases were assigned to the 
cytogenetic subgroups under consideration. Cases were assigned to one (n=983, 78%), 
two (n=228, 18%), three (n=53, 4%) or four (n=5, <1%) of the cytogenetic subgroups 
listed in Table 1. Among the remaining 425 (25%) cases, 152 (9%) had some other 
chromosomal abnormality, 131 (8%) had a normal karyotype and 142 (8%) did not 
achieve a cytogenetic result. With the exception of seven cases where t(9;22) or ETV6-
RUNX1 was observed in a high hyperdiploid (51-65 chromosomes) karyotype, primary 
chromosomal abnormalities did not co-exist in the same karyotype (Supplementary 
Table 1). In contrast, secondary abnormalities occurred together frequently and often in 
a non-random pattern.  
There was no significant variation in the ratio of boys to girls by chromosomal 
abnormality (Supplementary Table 2). Low hypodiploidy (30-39 chromosomes), iAMP21, 
IGH-CEBP, abnormal 9p and abnormal 17p were associated with older age. Patients with 
t(1;19)(q23;p13), t(9;22), MLL translocations, near haploidy (<30 chromosomes) and 
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abnormal 9p had higher WCCs at presentation whereas high hyperdiploid patients had 
lower WCCs.  
Table 1, Figure 2, supplementary table 3 and supplementary figures 1 and 2 describe the 
outcome of patients with different chromosomal abnormalities. There was little 
correlation between cytogenetics and failure to achieve a remission or death in first 
remission; six of the seven t(9;22) patients who died in first remission underwent bone 
marrow transplantation. ETV6-RUNX1 and high hyperdiploidy were associated with an 
improved outcome whereas t(9;22), iAMP21, MLL translocations, near haploidy, low 
hypodiploidy, t(17;19)(q23;p13), abnormal 17p and loss of 13q were associated with a 
higher risk of relapse and/or death. There were too few patients with an IGH-CEPB or 
IGH–ID4 fusion to assess their prognosis accurately.  
Among the 50 patients with abnormal 17p, 27 (54%) also had high hyperdiploidy (n=21) 
or ETV6-RUNX1 (n=6) (Supplementary Table 1). Abnormalities included i(17q) (n=17), 
del(17p) (n=7), der/dic(17p) (n=11), add(17p) (n=8)  and -17 (n=7). At least 42 (84%) 
of these 17p abnormalities resulted in loss of 17p13. The presence of abnormal 17p 
among patients with ETV6-RUNX1 or high hyperdiploidy did not adversely affect their 
relapse risk (HR=1.69, 95% CI 0.74-3.85, p=0.210), whereas for patients without ETV6-
RUNX1 or high hyperdiploidy the presence of an abnormal 17p conferred a three-fold 
increased risk of relapse (HR=3.17, 95% CI 1.76-5.74, p=0.0001). Given this difference 
and knowing that i(17q) correlates with high hyperdiploidy1, we examined the type of 
17p abnormality across cytogenetics subgroups. We saw some evidence of the high 
hyperdiploidy-i(17q) association [11/21 (52%) v 6/29 (21%), p=0.03] but did not 
observe any other relationship which might explain the differential effect of abnormal 
17p.  
A total of 44 patients had either a del(13q) (n=27), monosomy 13 (n=16) or both (n=1). 
These abnormalities were clearly secondary and frequently (24/44, 55%) coexisted with 
a known primary abnormality, particularly ETV6-RUNX1 (n=11), high hyperdiploidy (n=5) 
and t(1;19) (n=5) (Supplementary Table 2). There was no correlation between 
del(13q)/-13 and cytogenetic subgroup. Among 22 patients with a deletion and defined 
breakpoints, 16 (73%) involved 13q14. As with abnormal 17p, the effect of loss of 13q 
within the ETV6-RUNX1 and high hyperdiploid groups was not significant (HR=1.46, 95% 
CI 0.46-4.60, p=0.518). Although the effect of 13q loss among patients with other 
abnormalities was consistent with an increased relapse risk it was not significant 
(HR=1.78, 95% CI 0.94-3.39, p=0.078). 
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Previous studies have found triple trisomy (TT) (+4, +10, +17)11 or trisomy 18 (+18)12 
to be associated with an improved outcome. In this study, 419/562 (75%) and 484/562 
(86%) cases could be accurately classified by TT and +18 status, respectively. Only 
253/409 (62%) cases that were classified by both criteria were concordant (i.e. TT and 
+18 (n=190), or neither (n=63)), suggesting the criteria do not identify exactly the 
same patient populations. There was no difference in outcome by TT status (HR=0.80, 
95% CI 0.49-1.33, p=0.395) (Supplementary Figure 3). However, high hyperdiploid 
patients with +18 had a reduced risk of relapse compared to those with two copies of 
chromosome 18 (HR=0.44, 95% CI 0.26-0.74, p=0.002). As there was an overlap in the 
patient cohort between this and our previous study,12 we repeated the analysis after 
excluding patients treated on the ALL97 phase. The result was nearly identical (HR=0.37, 
95% CI 0.18-0.76, p=0.006).  
A multivariate Cox proportion hazards model was used to assess the significance of each 
cytogenetic abnormality that had been found to be significant in univariate analysis 
within the context of other risk factors. Table 2 and Supplementary Tables 3 and 4 show 
that six cytogenetic variables (iAMP21, t(9;22), ETV6-RUNX1, loss of 13q, abnormal 17p 
and high hyperdiploidy) retained their significance in the RFS and EFS models and five 
(iAMP21, t(9;22), ETV6-RUNX1, abnormal 17p and high hyperdiploidy) in the OS model. 
MLL translocations did not retain their prognostic significance in any of the models. There 
was no statistical interaction between ETV6-RUNX1 or high hyperdiploidy and the phase 
of trial (ALL97 versus ALL99) in the RFS, EFS or OS multivariate models. Individual poor 
risk chromosomal abnormalities were too rare to test for interaction reliably.  
The MLL subgroup was heterogeneous cytogenetically and comprised patients with 
t(4;11)(q21;q23)/MLL-AF4 (n=17), t(9;11)(p21~2;q23)/MLL-AF9 (n=5), 
t(11;19)(q23;p13)/MLL-ENL (n=1), t(10;11)(p12~14;q23)/MLL-AF10 (n=1) and 
unknown MLL partners (n=6). Patients with t(4;11) (n=17) were significantly older 
(median age 8.6 v 1.6 years, p=0.002) compared to other MLL patients (n=13), but 
there was no difference with respect to sex or WCC (data not shown). Most MLL patients 
had a common or pre-B immunophenotype (18/29, 62%), including seven t(4;11) 
patients. The remaining 11 (38%) patients (9 t(4;11), 1 t(11;19) and 1 unknown MLL 
partner) had a null or pro-B immunophenotype. As the median age of patients with a 
MLL translocation was 4 years, we examined the prognostic effect of MLL status among 
younger and older patients. Among patients under the age of 4 years, the presence of a 
MLL translocation was associated with a higher risk of relapse (HR=8.75 (95% CI 4.55, 
16.84), p<0.0001) but this was not the case among patients over 4 years old (HR=0.91 
(0.29, 2.83), p=0.865). Due to the strong correlation between t(4;11) and age in this 
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cohort, similar risks were observed when examining the risk of relapse associated with 
t(4;11) and other MLL translocations: HR=1.37 (0.51,3.68), p=0.529 and HR=5.94 
(3.06,11.52), p=0.0001, respectively. 
We classified 1547 patients hierarchically into three cytogenetic risk groups (Table 3). 
There was no significant difference in RFS, EFS or OS between the 1547 patients 
classified into these three cytogenetic risk groups and the 178 patients who could not be 
evaluated due to failed or missing cytogenetic data (supplementary table 3). We used 
outcome data from this study to derive this classification but there were exceptions. The 
decision to classify near haploidy, low hypodiploidy and t(17;19) as poor risk despite not 
being able to formally test these groups, is supported by the fact that the low EFS/OS 
observed is consistent with several previous studies1 and both near haploidy and low 
hypodiploidy were included in the trial risk stratification algorithm as high risk features. 
The MLL translocation group was included in the poor risk group despite not retaining its 
significance in the multivariate model because the univariate analysis was clearly 
significant and patients under the age of 2 years with a MLL translocation were treated 
as high risk in this trial. This, and other high risk criteria, meant that 18/30 (60%) 
patients with a MLL translocation were treated on HR1 or Regimen C. Poor risk 
abnormalities correlated with older age and higher WCC (Supplementary Table 2). Tables 
1, 2 and 3, Supplementary Tables 3, 4 and 5, Figure 2 and Supplementary Figure 1 and 
2 illustrate the strong correlation between cytogenetic risk group and outcome both in 
univariate and multivariate analysis. There was no statistical interaction between 
cytogenetic risk group and the phase of trial (ALL97 versus ALL99) in the RFS, EFS or OS 
multivariate models. 
Among 766 ALL99 patients who were assessed for early response and could be classified 
into a cytogenetic risk group, 83 (11%) patients were slow early responders (SER). SER 
percentage varied significantly by cytogenetic risk group: good 34/460 (7%), 
intermediate 22/211 (10%) and poor 27/95 (28%) (p<0.0001).  
We used this classification to examine the relationship between cytogenetics and relapse 
characteristics (Table 4). There was a strong correlation between cytogenetic risk group 
and the time to relapse. Patients in the poor cytogenetic risk group were more likely to 
relapse within 18 months of diagnosis, whereas those in the good  cytogenetic risk group 
were more likely to have later, off-treatment, relapses (p<0.0001). However, there was 
no correlation between the site of relapse and cytogenetic risk group whether divided by 
individual sites (as in Table 4) or dichotomously according to marrow involvement (data 
not shown). Finally, we examined the relationship between  cytogenetic risk group and 
relapse risk group, as used previously by us, to examine survival after relapse in the 
10 
 
UKALLR2 trial.13 Table 3 shows that relapses arising from the poor cytogenetic risk group 
were five times more likely to be classified as a high risk relapse compared to those 
occurring in the good  cytogenetic risk group (p<0.0001). 
 
DISCUSSION 
This dataset represents one of the largest and most comprehensive cytogenetic studies 
of childhood ALL yet published. The results provide compelling evidence for the 
prognostic significance of cytogenetics in this disease. As ALL99 patients fared better 
than their ALL97 counterparts, we assessed whether there was any interaction between 
cytogenetic parameters and protocol. No statistical interaction was observed suggesting 
that the improved outcome seen in ALL99 benefitted all patients irrespective of 
cytogenetic risk group. We have verified conclusively the excellent prognosis associated 
with ETV6-RUNX1 fusion and high hyperdiploidy.12, 14-16 Multivariate analyses confirms 
that these associations are independent of other risk factors. Moreover, contrary to 
reports from several other groups we did not observe any increased risk of late relapses 
associated with ETV6-RUNX1.17-19 The crude relapse rate in our study for ETV6-RUNX1 
patients was substantially lower, suggesting our treatment protocol might be averting 
the late relapses seen, for example, in the NOPHO study.17  
Outcome heterogeneity in high hyperdiploidy by specific trisomies has been debated for 
many years.1 We could not confirm the results of the Children’s Oncology Group study 
suggesting that high hyperdiploid patients with TT (+4,+10,+17) have a superior 
outcome.11 Rather, this analysis confirms our previous findings regarding the favourable 
outcome of high hyperdiploid patients with +18.12 There are a number of differences 
between the two studies which may account for this discrepancy. Firstly, the Children’s 
Oncology Group analysis was not restricted to high hyperdiploid patients and thus their 
“non triple trisomy” group included patients with other abnormal and normal karyotypes. 
While this approach includes very rare non-high hyperdiploid cases with TT, it introduces 
substantial heterogeneity into the analysis making the results more difficult to interpret. 
In contrast, our analysis represents simple comparison within the high hyperdiploid 
subgroup between patients with and without a triple trisomy. Secondly, although the  
Children’s Oncology Group study comprised over 5000 patients, they were treated over a 
longer period of time (11 years) and in a different era (1988-1999). Thirdly, poor 
chromosome morphology results in incomplete classification rates and also chromosome 
misclassification; both of which are likely contributing factors. FISH screening will resolve 
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these two technical problems and future, more accurate datasets, will hopefully resolve 
this ongoing question.  
This study has confirmed the poor outcome associated with t(9;22), near haploidy, low 
hypodiploidy, MLL translocations, t(17;19) and iAMP21,.1 This was despite patients with 
the t(9;22), near haploidy, low hypodiploidy and MLL translocations (<2 years) receiving 
more intensive treatment. However, it should be noted that equivalent cytogenetic 
subgroups treated on the predecessor trial, UKALLXI, had an extremely poor outcome 
(near haploidy (EFS at 5 yrs 0%); t(4;11) (13%) and t(9;22) (27%))20 suggesting that 
the risk stratification of these rare cytogenetic subgroups was beneficial. Although 
patients with a MLL translocation had an inferior outcome overall, there was clear 
evidence of outcome heterogeneity within this group. Our analysis suggests that both 
age and t(4;11) may be important factors. Due to the relatively small number of patients 
in this subgroup and the strong correlation between t(4;11) and age, we were not able 
to determine which factor is driving this heterogeneity. The situation is further 
confounded by the fact that 18/30 were treated as high risk either on the basis of a MLL 
translocation or other risk features. While it is clear from previous studies that age is an 
important prognostic factor for patients with MLL translocations, most have compared 
infants (<1 year) with children (>1 year) or just considered infants21-23; and our study 
did not include any infants. Heterogeneity of outcome by MLL partner, with t(4;11) and 
t(9;11) faring poorly, has also been suggested especially among children (>1 year 
old).21, 22 In addition, a study from St Jude Children’s Research Hospital reported a very 
good outcome for t(4;11) patients albeit on just a handful of cases.16 This important 
clinical issue will need to be addressed using a larger cohort of children. However, a 
recent gene expression study which reported a link between differential expression of 
HOXA genes and outcome among infants with t(4;11)24 raises the possibility that 
secondary genetic alterations could be responsible for this heterogeneity.  
We found that patients with abn(17p) had a significantly inferior outcome and in 
particular a higher rate of relapse, but this finding was restricted to patients without one 
of the good risk abnormalities of ETV6-RUNX1 and high hyperdiploidy. This finding 
mirrors the situation observed in AML, whereby the presence of poor risk cytogenetic 
abnormalities do not affect the good prognosis of patients with t(15;17), t(8;21) or 
inv(16).25 We have recently reported that abn(17p)/-17 are independent adverse risk 
factors in AML.25 Studies in childhood ALL have been limited to i(17q) within the high 
hyperdiploidy subgroup.1 This study confirms our previous observations that abn(17p) 
does not negate the good prognosis associated with high hyperdiploidy.12 In adult ALL, 
abn(17p) was not a risk factor in BCP-ALL but results in T-ALL were strongly suggestive 
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of an association with poor outcome.26, 27 In AML, abnormalities of 17p correlate with 
complex karyotypes and p53 inactivation/mutation.28 While p53 mutations are rare in 
childhood ALL, it has been suggested that they occur more frequently in high risk 
disease.29 Independent studies are required to confirm these observations and unravel 
the nature of these aberrations. 
In 2000, Heerema et al30 reported that del(13q) was associated with an increased risk of 
relapse in childhood ALL, although the risk was not independent in multivariate analysis 
and did not extend to OS. We included patients with monosomy 13 in our analysis and 
found that the increased risk of relapse was independent of other risk factors although, 
again, OS was not affected. While it is tempting to speculate that the RB1 gene is the 
target of this abnormality, this requires verification.  
Historically several groups have reported that t(1;19) has an inferior outcome unless 
treated by more intensive treatment.1 However, in this and our previous study, 
UKALLXI20, patients with t(1;19) have always fared slightly but not significantly better 
than the average (Table 1). The St Jude Children’s Research Hospital recently reported 
that t(1;19) patients have an increased risk of CNS relapse.16, 31 Among our 50 t(1;19) 
patients, only 6 (12%) relapsed and 3 (50%) involved the CNS. However, with so few 
relapses occurring in this subgroup it is impossible to conclude that this rate is truly 
higher than the overall rate of 110/351 (31%).  
The prognostic relevance of dic(9;20) is currently the subject of debate with several 
groups reporting association with other poor risk features and increased incidence in 
high risk cohorts.32, 33 Our data, however, indicate no evidence for an increased risk of 
relapse or inferior outcome in this subgroup. This abnormality is both rare and 
heterogeneous at the molecular level34; these two factors make assigning a reliable 
prognosis to patients with dic(9;20) very difficult.  
The literature is contradictory with respect to the prognostic relevance of 9p 
abnormalities/CDKN2A deletions in childhood ALL.20, 35-40 The evidence from paediatric T-
ALL cohorts is more consistent for a relationship between CDKN2A/9p deletions and an 
inferior outcome.41, 42 However, it should be noted that not all patients with an 
abnormality of 9p have a CDKN2A deletion and vice versa.1, 35, 43 Therefore the terms are 
not mutually exclusive, despite considerable overlap. Our cytogenetic based observations 
are consistent with the recent EORTC study on paediatric BCP-ALL, which used molecular 
methods to assess CDKN2A copy number, and found no evidence for an association 
between CDKN2A deletion and outcome.38  
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Numerous studies over the past five years have shown that outcome after relapse is 
highly heterogenous.3 While there is a consensus regarding the most relevant risk 
factors governing post-relapse survival (initial response, time of relapse and site of 
relapse) less is known about the relationship between cytogenetics and these factors. 
Using a cytogenetic risk index outlined in Table 3, we found a strong correlation between 
poor risk cytogenetics and slow early response as well as early relapse. Furthermore 
there was a strong correlation between  cytogenetic risk group and the relapse risk 
groups used in UKALLR2.13 These findings could be used in conjunction with MRD data to 
identify patients at greatest risk of multiple treatment failure who would benefit most 
from early intervention with alternative therapies. 
This study has many strengths including size, long follow-up, quality and extent of 
cytogenetic analysis and comprehensive statistical analysis. However, it does have some 
limitations. As this is the first time that the cytogenetic risk groups in table 4 have been 
proposed in childhood ALL, they will require validation in independent cohorts. Recent 
array studies have highlighted a plethora of novel focal deletions of B-cell differentiation 
and cell cycle genes in childhood ALL.32, 44 Unfortunately we have not been able to 
incorporate data on these abnormalities into this study due to a lack of suitable material. 
Although, IKZF1 deletions have been reported to confer a higher risk of relapse, the 
largest effect was seen within the t(9;22) subgroup which is already a well established 
poor risk subgroup.44 In addition, den Boer et al32 reported that many of the micro-
deletions correlated with either the t(9;22)/BCR-ABL1 subgroup or the newly described 
BCR-ABL1-like subgroup. Importantly, the BCR-ABL1-like subgroup did not correlate with 
any of the major cytogenetic subgroups. Hence while it will be important to assess the 
prognostic relevance of these micro-deletions in the context of these results; we do not 
think that the absence of such data significantly alters the key findings in this study.  
The findings from this large and comprehensively characterised cohort of childhood ALL 
demonstrate the importance of cytogenetics in the management of patients with this 
disease. We have confirmed that individual chromosomal abnormalities are strong 
independent predictors of outcome, especially risk of relapse. Moreover, we have shown 
that diagnostic cytogenetics not only identifies patients with a higher rate of relapse but 
predicts those who are less likely to respond well to treatment after relapse. In the 
forthcoming NCRI ALL2010 paediatric trial the following chromosomal abnormalities will 
be classified as high risk - t(9;22), iAMP21, MLL translocations, near haploidy, low 
hypodiploidy and t(17;19). 
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Figure Legends 
Figure 1: ALL97/99 treatment regimens.  
CMT=Continuing maintenance therapy. MTX=Methotrexate. WCC=white blood cell count. 
RER=rapid early response. SER=slow early response. CCG=Children’s Cancer Study 
Group. BFM=Berlin Frankfurt Munster consolidation. DDI=double delayed intensification. 
IM=interim maintenance. DI=delayed intensification. CT=continuing therapy. * Third 
block was randomised in first year. 
 
Figure 2:  Kaplan Meier graphs showing the relapse free survival for (a) individual 
chromosomal abnormalities that were significant in univariate analysis, (b) cytogenetic 
risk groups.  
For the purposes of drawing this graph patients were classified hierarchically in the order 
ETV6-RUNX1, t(9;22), MLL translocations, iAMP21, high hyperdiploidy, abnormal 17p, 
loss of 13q.
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Table 2: Final multivariate Cox models of relapse free survival for individual chromosomal abnormalities and 
the cytogenetic risk groups 
Variable 
1
 Hazard Ratio 
3
 P value 95% CI 
    
Individual chromosomal abnormality 
6
 
ALL99 v ALL97 0.71 0.0031 (0.56,0.89) 
Dexa v Pred 
4
 0.62 0.0001 (0.49,0.79) 
iAMP21 4.69 <0.0001 (2.94,7.48) 
WCC 
2
 1.23 <0.0001 (1.13,1.35) 
Age 1.05 0.0003 (1.02,1.08) 
t(9;22) 2.65 0.0001 (1.62,4.35) 
ETV6-RUNX1 0.53 0.0002 (0.38,0.74) 
High hyperdiploidy 0.68 0.0065 (0.51,0.90) 
Abnormal 17p 2.21 0.0012 (1.37,3.57) 
Loss of 13q 1.99 0.0130 (1.16,3.43) 
    
Cytogenetic Risk Group 
5
 
ALL99 v ALL97 0.70  0.0019 (0.55,0.87) 
Dexa v Pred 
4
 0.62 0.0001 (0.49,0.79) 
Good v Intermediate Risk 0.70  0.0110 (0.53,0.92) 
Poor v Intermediate Risk 3.01 <0.0001 (2.23,4.06) 
WCC 
2
 1.16  0.0010 (1.06,1.26) 
Age 1.05 0.0004 (1.02,1.08) 
 
Notes: (1) Variables are listed in the order in which they entered the model; (2) WCC was transformed to 
ln(WCC+1) before being entered in the model; (3) The hazard ratio for the good and poor cytogenetic risk 
groups is relative to the intermediate risk group; (4) Dexamethasone v Prednisolone; (5) See table 4 for 
definition of cytogenetic risk group; (6) Sex and MLL translocations were assessed in the stepwise multivariate 
analysis but did not make it into the final model. 
 
Abbreviations: WCC, white cell count 
Definitions: High hyperdiploidy, 51-65 chromosomes 
3 
 
Table 3: Definition of cytogenetic risk groups 
Cytogenetic 
Risk Group 
Chromosomal abnormalities Notes 
Good High hyperdiploidy (51-65 
chromosomes) 
ETV6-RUNX1 
Irrespective of the 
presence of poor 
risk abnormalities, 
except  
t(9;22)(q34;q11).  
Intermediate t(1;19)(q23;p13)  
IGH-CEBP  
IGH-ID4  
del(6q)  
abnormal 9p  
abnormal 11q  
dup(1q)  
-7  
dic(9;20)(p13;q11)  
dic(9;12)(p11~21;p11~13) 
any other abnormality 
normal karyotype 
 
Poor t(9;22)(q34;q11.2) 
iAMP21 
MLL translocations 
near Haploidy (<30 
chromosomes) 
low hypodiploidy (30-39 
chromosomes) 
t(17;19)(q23;p13) 
abnormal 17p 
loss of 13q 
In the absence of 
good risk 
abnormalities, 
except in the 
situation of 
t(9;22) with high 
hyperdiploidy. 
  
4 
 
Table 4: Relationship between cytogenetic risk group and response rate, time of relapse, site of relapse and 
relapse risk group. 
Relapse Criteria 
All cases 
1
  
n (%) 
Cytogenetic Risk Group n (%) 
2
 
Good Intermediate  Poor 
     
Total Relapses 309 (20%) 129 (100%) 98 (100%) 82 (100%) 
     
Time of relapse 
<18m 69 (22%) 8 (6%) 24 (25%) 37 (45%) 
>18m and <6m EOT 67 (22%) 28 (22%) 25 (26%) 14 (17%) 
>6m EOT 173 (56%) 93 (72%) 49 (50%) 31 (38%) 
     
Site of relapse 
Isolated marrow 180 (58%) 69 (54%) 57 (58%) 54 (66%) 
Isolated CNS 51 (17%) 22 (17%) 19 (19%) 10 (12%) 
Isolated other 15 (5%) 8 (6%) 4 (4%) 3 (4%) 
Combined 63 (20%) 30 (23%) 18 (18%) 15 (18%) 
     
Relapse Risk Group 
3
 
Standard Risk 19 (6%) 13 (10%) 3 (3%) 3 (4%) 
Intermediate Risk 217 (70%) 104 (81%) 72 (74%) 41 (50%) 
High Risk 73 (24%) 12 (9%) 23 (24%) 38 (46%) 
  
Notes:  
(1) Excludes cases with failed or no cytogenetics.  
 
(2) See table 4 for definition of cytogenetic risk group  
 
(3) Standard risk, isolated extramedullary relapses occurring 6 months or more after the EOT; Intermediate risk, 
isolated extramedullary relapses occurring on therapy or within 6 months of EOT, combined relapses occurring 
18m or more after diagnosis and isolated marrow relapses occurring 6 months after the EOT; High risk, 
combined relapses occurring with 18m of diagnosis and isolated marrow relapses occurring on therapy or 
within 6 months of EOT.  
 
Abbreviations: EOT, end of frontline treatment  
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Supplementary Table 2: Incidence and clinical characteristics of children with B-cell precursor acute lymphoblastic 
leukaemia (BCP-ALL) by chromosomal abnormality and cytogenetic risk group 
Chromosomal abnormality 
Number (%) of 
patients 1 
Sex ratio 
(M:F) 
Age (years) 
Median (IQR) 
WCC (x109/L) 
Median (IQR) 
All patients 1725 (100%) 1:0.83 4 (3,8) 9.9 (4.2,31.5) 
Primary Chromosomal/Genetic abnormalities 
High hyperdiploidy 562 (38%) 1: 0.8 3 (2,6)** 7.5 (3.7,19.7)** 
ETV6-RUNX1 368 (25%) 1: 0.7 4 (3,5) ** 10.7 (5, 33.7) 
t(1;19)(q23;p13) 50 (4%) 1:1.27 3 (2,8) 26.2 (16.2, 39)** 
t(9;22)(q34;q11.2) 43 (3%) 1:0.65 6 (3,12) 35 (11,200)** 
iAMP21 29 (2%) 1:0.93 8 (7,12)** 3.7 (2.4,13.9)** 
MLL translocations 30 (2%) 1:0.88 4 (1,12) 129 (32,205)** 
Near Haploidy 10 (1%) 1:1 6 (4,8) 50 (16,135)* 
Low hypodiploidy 8 (1%) 1:1 12 (10,14)* 5.6 (4.1,14.2) 
IGH-CEBP 7 (NA) 1:1.33 11 (9,14)* 5.9 (4.6,103) 
IGH-ID4 3 (NA) 1:0 12 4.5 
t(17;19)(q23;p13) 2 (0.1%) 1:1 9 6.7 
     
Secondary abnormalities 
del(6q) 77 (5%) 1:0.67 4 (3,7) 8.5 (3.4,23.4) 
abnormal 9p 160 (11%) 1:0.86 6 (3,11)* 12.8 (5.2,58)* 
abnormal 11q 68 (5%) 1:1.06 4 (3,8) 8.4 (5,22.2) 
abnormal 17p 44 (3%) 1:0.92 5 (3,10)* 9.5 (5.7, 36.5) 
Loss of 13q 50 (4%) 1:0.76 6 (4,9) 12.2 (4.6,34) 
dup(1q) 41 (3%) 1:0.86 4 (3,7) 9 (4.2,23.7) 
-7 23 (2%) 1:0.64 4 (3,12) 11.4 (4,49.6) 
dic(9;20)(p13;q11) 13 (1%) 1:0.86 7 (5,11) 10.7 (4.2,20.1) 
dic(9;12)(p11~21;p11~13) 15 (1%) 1:0.15 11 (3,14) 15 (3.6, 33.9) 
Cytogenetic Risk Group 2 
Good Risk 923 1:0.77 4 (2,6)** 8.5 (4.1, 24)** 
Intermediate Risk 458 1:0.89 5 (3,10) 12.6 (4.6,36.9) 
Poor Risk 166 1:0.84 7 (4,12) 16.1 (5.2, 91.5) 
 
Notes: (1) The incidence has been calculated using the total number of patients tested for each abnormality by cytogenetics, FISH 
or RT-PCR: High hyperdiploidy (n=1486); ETV6-RUNX1 (n=1451);  t(1;19), abnormal 11q, dic(9;12) (n=1420); t(17;19), del(6q), 
abnormal 9p, abnormal 17p, loss of 13q, dup(1q), -7, dic(9;20) (n=1419); t(9;22) (n=1633); iAMP21 (n=1449), Other MLL 
translocations, t(4;11) (n=1627); near haploidy, low hypodiploidy (n=1434). No incidence has been given for IGH-CEBP and 
IGH-ID4 has both these abnormalities were identified by selected FISH screening. (2) See table 4 for definition of cytogenetic risk 
group. For the good and poor cytogenetic risk groups each has been compared to the intermediate group. Abbreviations: IQR, 
inter-quartile range; WCC, white cell count. Symbols: * P <0.01, **P<0.001. Definitions: High hyperdiploidy, 51-65 
chromosomes; near haploidy, <30 chromosomes; low hypodiploidy, 30-39 chromosomes. 
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Supplementary Table 3: Outcome of children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) by 
chromosomal abnormality and cytogenetic risk group showing the comparator group for individual analyses. 
 
Chromosomal abnormality Total (%) 
No 
Remission        
N (%) 
Deaths 
in 1st 
remission 
N (%) 
Relapses 
N (%) 
RFS at 5 Yrs 
%  (95%CI) 
EFS at 5Yrs 
% (95% CI) 
OS at 5Yrs 
% (95% CI) 
All patients 1725 (100) 16 (1) 57 (3) 351 (20) 81 (79-83) 78 (76-80) 87 (86-89) 
Primary abnormalities 
High hyperdiploidy 
Yes 562 (38) 3 (1) 11 (2) 85 (15) 86 (83-89) 84 (81-87) 93 (91-95) 
No 924 (62) 11(1) 38 (4) 212 (23) 78 (76-81) 75 (72-78) 85 (82-87) 
 ETV6-RUNX1 
Yes 368 (25) 2 (1) 5 (1) 47 (13) 89 (86-92) 89 (85-91) 96 (94-98) 
No 1083 (75) 10 (1) 42 (4) 240 (22) 79 (76-81) 75 (73-78) 85 (83-87) 
 t(1;19)(q23;p13) 
Yes 50 (4) 0 (0) 4 (8) 6 (12) 87 (74-94) 80 (66-89) 84 (71-92) 
No 1370 (97) 13(1) 42 (3) 277 (20) 81 (79-83) 79 (76-81) 88 (86-89) 
 t(9;22)(q34;q11.2) 
Yes 43 (3) 1 (2) 7 (16) 18 (42) 56 (38-70) 44 (29-58) 58 (42-71) 
No 1590 (97) 13 (1) 46 (3) 309 (19) 82 (80-84) 79 (77-81) 89 (87-90) 
 iAMP21 
Yes 29 (2) 1 (3) 0 (0) 22 (76) 27 (12-44) 26 (12-43) 69 (49-82) 
No 1420 (98) 11(1) 46 (3) 266 (19) 83 (80-85) 80 (77-82) 88 (87-90) 
 MLL translocations 
Yes 30 (2) 0 (0) 2 (7) 13 (43) 55 (35-71) 50 (31-66) 60 (41-75) 
No 1597 (98) 14 (1) 51 (3) 315 (20) 82 (80-84) 79 (77-81) 88 (86-90) 
 Near Haploidy 
Yes 10 (1) 0 (0) 0 (0) 6 (60) 44 (14-72) 40 (12-67) 40 (12-67) 
No 1425(99) 14(1) 47 (3) 287 (20) 81 (79-83) 78 (76-80) 88 (86-90) 
 Low hypodiploidy 
Yes 8 (1) 0 (0) 0 (0) 4 (50) 50 (15-78) 50 (15-78) 50 (15-78) 
No 1426(99) 14(1) 47 (3) 289 (20) 81 (79-83) 78 (76-80) 88 (86-89) 
 IGH-CEBP 
Yes 7 (NA) 0 (0) 0 (0) 2 (29) 71 (26-92) 71 (26-92) 86 (33-98) 
No 86 (NA) 3 (4) 7 (8) 28 (33) 70 (59-79) 63 (52-72) 75 (65-83) 
 IGH-ID4 
Yes 3 (NA) 0 (0) 0 (0) 0 (0) 100 (-) 100 (-) 100 (-) 
No 90 (NA) 3 (3) 7(8) 30 (33) 69 (58-78) 62 (51-71) 75 (65-83) 
t(17;19)(q23;p13) 
Yes 2 (0.1) 0 (0) 0 (0) 2 (100) - - - 
No 1417(99.9) 13(1) 46(3) 281 (20) 82 (80-84) 79 (76-81) 88 (86-89) 
Secondary abnormalities 
 del(6q) 
Yes 77 (5) 0 (0) 2 (3) 17 (22) 80 (69-87) 79 (68-87) 87 (77-93) 
No 1342 (95) 13 (1) 44 (3) 266 (20) 82 (80-84) 79 (76-81) 88 (86-89) 
 abnormal 9p 
Yes 160 (11) 2 (1) 5 (3) 38 (24) 77 (70-83) 74 (67-80) 86 (79-90) 
No 1259 (89) 11 (1) 41 (3) 245 (20) 82 (80-84) 79 (77-81) 88 (86-90) 
 abnormal 11q 
Yes 68 (5) 1 (2) 3 (4) 12 (18) 81 (70-89) 78 (66-86) 87 (76-93) 
No 1352 (95) 12 (1) 43 (3) 271 (20) 82 (79-84) 79 (76-81) 88 (86-89) 
 abnormal 17p 
Yes 50 (4) 1 (2) 0 (0) 18 (36) 65 (50-77) 64 (49-76) 76 (61-86) 
No 1369 (97) 12 (1) 46 (3) 265 (19) 82 (80-84) 79 (77-81) 88 (86-90) 
loss of 13q 
Yes 44 (3) 2 (5) 1 (2) 14 (32) 68 (52-80) 66 (50-78) 82 (67-91) 
No 1375 (97) 11 (1) 45 (3) 269 (20) 82 (80-84) 79 (77-81) 88 (86-89) 
dup(1q) 
Yes 41 (3) 1 (2) 0 (0) 8 (20) 82 (66-91) 80 (64-90) 95 (82-99) 
No 1378 (97) 12 (1) 46 (3) 275 (20) 82 (79-84) 79 (76-81) 87 (86-89) 
 -7 
Yes 23 (2) 1 (4) 0 (0) 7 (30) 77 (54-90) 74 (51-87) 87 (65-96) 
No 1396 (98) 12 (1) 46 (3) 276 (20) 82 (80-84) 79 (76-81) 88 (86-89) 
dic(9;20)(p13;q11) 
Yes 13 (1) 0 (0) 1 (8) 3 (23) 77 (44-92) 77 (44-92) 92 (57-99) 
No 1406 (99) 13 (1) 45 (3) 280 (20) 82 (80-84) 79 (76-81) 88 (86-89) 
dic(9;12)(p11~21;p11~3) 
Yes 15 (1) 0 (0) 0 (0) 3 (20) 80 (50-93) 80 (50-93) 87 (56-97) 
No 1405 (99) 13 (1) 46 (3) 280 (20) 82 (79-84) 79 (76-81) 88 (86-89) 
Cytogenetic Risk Group 1 
  Good Risk Yes 923 (54) 5 (1) 15 (2) 129 (14) 88 (85-90) 86 (84-88) 94 (93-96) 
  Intermediate Risk Yes 458 (27) 5 (1) 23 (5) 98 (21) 80 (76-84) 76 (72-80) 85 (81-88) 
  Poor Risk Yes 166 (10) 4 (2) 10 (6) 82 (49) 50 (42-58) 45 (37-52) 61 (53-68) 
  No Cytogenetic Group No 178 (10) 2 (1) 9 (5) 42 (24) 77 (69-82) 72 (65-78) 83 (76-87) 
 
Notes: (1) See table 4 for definition of cytogenetic risk group. Abbreviations: CI, confidence interval; Definitions: High 
hyperdiploidy, 51-65 chromosomes; near haploidy, <30 chromosomes; low hypodiploidy, 30-39 chromosomes.
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Supplementary Table 4: Final multivariate Cox models of Event Free Survival for individual chromosomal abnormalities and 
the cytogenetic risk groups 
Variable 1 Hazard Ratio 3 P value 95% CI 
Individual chromosomal abnormality6 
ALL99 v ALL97 0.75 0.0059 (0.60,0.92) 
Dexa v Pred 4 0.71 0.0023 (0.57,0.89) 
Age 1.05 0.0001 (1.02,1.08) 
WCC 2 1.23 <0.0001 (1.14,1.34) 
iAMP21 3.84 <0.0001 (2.45,6.02) 
t(9;22) 2.89 <0.0001 (1.90,4.38) 
ETV6-RUNX1 0.49 <0.0001 (0.36,0.68) 
High hyperdiploidy 0.65 0.0009 (0.50,0.84) 
Abnormal 17p 1.89 0.0072 (1.19,3.01) 
Loss of 13q 1.92 0.0097 (1.17,3.13) 
 
Cytogenetic Risk Group 5 
ALL99 v ALL97 0.74 0.0039 (0.60,0.91) 
Dexa v Pred 4 0.71 0.0023 (0.57,0.89) 
Good v Intermediate Risk 0.64 0.0005 (0.50,0.83) 
Poor v Intermediate Risk 2.71 <0.0001 (2.07,3.56) 
WCC 2 1.17 0.0001 (1.08,1.26) 
Age 1.05 0.0003 (1.02,1.07) 
 
Notes: (1) Variables are listed in the order in which they entered the model; (2) WCC was transformed to ln(WCC+1) before being 
entered in the model; (3) The hazard ratio for the good and poor cytogenetic risk groups is relative to the intermediate risk group; (4) 
Dexamethasone v Prednisolone; (5) See table 4 for definition of cytogenetic risk group; (6) Sex and MLL translocations were assessed 
in the stepwise multivariate analysis but did not make it into the final model. Abbreviations: WCC, white cell count. Definitions: 
High hyperdiploidy, 51-65 chromosomes 
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Supplementary Table 5: Final multivariate Cox models of Overall Free Survival for individual chromosomal abnormalities 
and the cytogenetic risk groups 
Variable 1 Hazard Ratio 3 P value 95% CI 
Individual chromosomal abnormality6 
ALL99 v ALL97 0.71 0.0150 (0.54,0.94) 
Dexa v Pred 4 0.85 0.2490 (0.64,1.12) 
Age 1.07 <0.0001 (1.04,1.11) 
WCC 2 1.33 <0.0001 (1.20,1.47) 
ETV6-RUNX1 0.28 <0.0001 (0.17,0.46) 
High hyperdiploidy 0.49 0.0001 (0.34,0.69) 
t(9;22) 2.42 0.0004 (1.48,3.94) 
iAMP21 2.49 0.0033 (1.36,4.59) 
Abnormal 17p 1.99 0.0170 (1.13,3.50) 
    
Cytogenetic Risk Group 5 
ALL99 v ALL97 0.68 0.0069 (0.52,0.90) 
Dexa v Pred 4 0.85 0.2490 (0.64,1.12) 
Good v Intermediate Risk 0.48 <0.0001 (0.34,0.67) 
Poor v Intermediate Risk 2.50 <0.0001 (1.80,3.48) 
WCC 2 1.27 <0.0001 (1.15,1.40) 
Age 1.07 <0.0001 (1.04,1.10) 
 
Notes: (1) Variables are listed in the order in which they entered the model; (2) WCC was transformed to ln(WCC+1) before being 
entered in the model; (3) The hazard ratio for the good and poor cytogenetic risk groups is relative to the intermediate risk group; (4) 
Dexamethasone Vs Prednisolone; (5) See table 4 for definition of cytogenetic risk group; (6) Sex, MLL translocations and loss of 13q 
were assessed in the stepwise multivariate analysis but did not make it into the final model. Abbreviations: WCC, white cell count 
Definitions: High hyperdiploidy, 51-65 chromosomes  
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Supplementary figure 1: Kaplan Meier graphs showing the event free survival for (a) individual chromosomal 
abnormalities that were significant in univariate analysis, (b) cytogenetic risk groups. NB. For the purposes of drawing 
this graph patients were classified hierarchically in the order ETV6-RUNX1, t(9;22), MLL translocations, iAMP21, high 
hyperdiploidy, abnormal 17p, loss of 13q. 
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Supplementary figure 2: Kaplan Meier graphs showing the overall survival for (a) individual chromosomal 
abnormalities that were significant in univariate analysis, (b) cytogenetic risk groups. NB. For the purposes of drawing 
this graph patients were classified hierarchically in the order ETV6-RUNX1, t(9;22), MLL translocations, iAMP21, high 
hyperdiploidy, abnormal 17p, loss of 13q. 
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Supplementary figure 3: Kaplan Meier graphs showing relapse-free survival for high hyperdiploid patients with and 
without (A) triple trisomy (+4,+10,+17) and (B) trisomy 18 .   
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